Contents

Search

ceftaroline (Teflaro)

Indications: - treatment of bacterial infections due to susceptible organisms - bacterial skin infections including MRSA - community-acquired pneumonia (except MRSA) - multidrug-resistant Streptococcus pneumoniae [3] Contraindications: - not approved for children (< 18 years of age) - pregnancy category: B - safety in lactation: ? Dosage: - 600 mg IV every 12 hours Powder: - 400 & 600 mg vials - reconstitute with 20 mL of sterile water - must be added to at least 250 mL of a diluent such as normal saline or D5W prior to infusion - solution stable for 6 hours at room temperature or overnight refrigerated Dosage adjustment in renal failure: - 400 mg for creatinine clearance < 50 mL/min - 300 mg for creatinine clearance < 50 mL/min - 200 mg for ESRD or hemodialysis - all dosing every 12 hours Antimicrobial activity: - Gram-positive bacteria - Staphylococcus (MSSA, MRSA) - linezolid, daptomycin & vancomycin resistant S aureus [3] - Streptococcus - multidrug-resistant Streptococcus pneumoniae [3] - Gram-negative bacteria - Haemophilus influenzae - Klebsiella pneumoniae - Moraxella catarrhalis - Escherichia coli [5] - does NOT cover: Enterococcus, Pseudomonas, most anaerobes Adverse effects: - rash (3%) - diarrhea (5%), constipation (2%) - nausea (4%), vomiting (2%) - increased transaminases (2%), hyperkalemia (2%) - phlebitis (2%) Drug interactions: - none reported, no studies - does not appear to interact with cyt P450 Mechanism of action: - 1st cephalosporin with activity against MRSA

Interactions

drug adverse effects of cephalosporins

General

cephalosporin, 5th generation

Database Correlations

PUBCHEM correlations

References

  1. Physician's First Watch for November 1, 2010 Massachusetts Medical Society http://www.jwatch.org FDA NEWS RELEASE, Oct. 29, 2010 FDA Approves Teflaro for Bacterial Infections http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm231594.htm
  2. Prescriber's Letter 18(1): 2011 New Drug: Teflaro (Ceftaroline) Detail-Document#: 270113 (subscription needed) http://www.prescribersletter.com
  3. Medical Knowledge Self Assessment Program (MKSAP) 16, 17. American College of Physicians, Philadelphia 2012, 2015
  4. Saravolatz LD, Stein GE, Johnson LB. Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2011 May;52(9):1156-63 PMID: 21467022
  5. Deprecated Reference